tetano
Editor, Senior Moderator
Rheumatol Int
. 2022 Feb 5.
doi: 10.1007/s00296-021-05069-x. Online ahead of print.
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
Arun Prabhahar[SUP] #[/SUP][SUP] 1 [/SUP], G S R S N K Naidu[SUP] #[/SUP][SUP] 2 [/SUP], Prabhat Chauhan[SUP] 1 [/SUP], Aravind Sekar[SUP] #[/SUP][SUP] 3 [/SUP], Aman Sharma[SUP] 2 [/SUP], Alok Sharma[SUP] 4 [/SUP], Asheesh Kumar[SUP] 5 [/SUP], Ritambhra Nada[SUP] 3 [/SUP], Manish Rathi[SUP] 1 [/SUP], Harbir Singh Kohli[SUP] 1 [/SUP], Raja Ramachandran[SUP] 6 [/SUP]
Affiliations
Abstract
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
Keywords: ANCA-associated vasculitis; Auto-immunity; COVID-19 vaccine; Glomerulonephritis; SARS-CoV-2 vaccine.
. 2022 Feb 5.
doi: 10.1007/s00296-021-05069-x. Online ahead of print.
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
Arun Prabhahar[SUP] #[/SUP][SUP] 1 [/SUP], G S R S N K Naidu[SUP] #[/SUP][SUP] 2 [/SUP], Prabhat Chauhan[SUP] 1 [/SUP], Aravind Sekar[SUP] #[/SUP][SUP] 3 [/SUP], Aman Sharma[SUP] 2 [/SUP], Alok Sharma[SUP] 4 [/SUP], Asheesh Kumar[SUP] 5 [/SUP], Ritambhra Nada[SUP] 3 [/SUP], Manish Rathi[SUP] 1 [/SUP], Harbir Singh Kohli[SUP] 1 [/SUP], Raja Ramachandran[SUP] 6 [/SUP]
Affiliations
- PMID: 35124725
- DOI: 10.1007/s00296-021-05069-x
Abstract
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
Keywords: ANCA-associated vasculitis; Auto-immunity; COVID-19 vaccine; Glomerulonephritis; SARS-CoV-2 vaccine.